-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Cardiovascular and cerebrovascular diseases have become one of the common diseases, and the scale of the related drug market continues to expand
.
According to data from Minai.
com, it is expected that the sales scale of cardiovascular and cerebrovascular proprietary Chinese medicines in China's urban physical pharmacies will exceed 13 billion yuan in 2022, a year-on-year increase of more than 5%.
3 billion "first aid miracle medicine" Angong Niuhuang Pill will reach a new high, 13 exclusive products "Baping"; 20 brands sold more than 100 million, 5 rose by more than 30%, Tongrentang, Tasly and Buchang led the way
.
.
According to data from Minai.
com, it is expected that the sales scale of cardiovascular and cerebrovascular proprietary Chinese medicines in China's urban physical pharmacies will exceed 13 billion yuan in 2022, a year-on-year increase of more than 5%.
3 billion "first aid miracle medicine" Angong Niuhuang Pill will reach a new high, 13 exclusive products "Baping"; 20 brands sold more than 100 million, 5 rose by more than 30%, Tongrentang, Tasly and Buchang led the way
.
Cardiovascular proprietary Chinese medicine pharmacies sold out, and the market of tens of billions continued to expand
Sales of cardiovascular and cerebrovascular proprietary Chinese medicines in China's urban physical pharmacies in recent years (: 100 million yuan)
Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern
com: China's urban physical pharmacy drug terminal competition pattern
Cardiovascular and cerebrovascular diseases have become one of the common diseases, and the scale of the related drug market continues to expand
.
According to data from Minai.
com, the terminal cardiovascular and cerebrovascular proprietary Chinese medicine market in China's urban physical pharmacies has maintained a growth trend in recent years, and is expected to exceed the 13 billion yuan mark in 2022, a year-on-year increase of more than 5%, which is the third major treatment category
after the use of drugs for respiratory diseases and digestive diseases.
.
According to data from Minai.
com, the terminal cardiovascular and cerebrovascular proprietary Chinese medicine market in China's urban physical pharmacies has maintained a growth trend in recent years, and is expected to exceed the 13 billion yuan mark in 2022, a year-on-year increase of more than 5%, which is the third major treatment category
after the use of drugs for respiratory diseases and digestive diseases.
From the perspective of manufacturer structure, Beijing Tongrentang's market share continues to be the leader, more than 20%, Tasly, Buchang Pharmaceutical, etc.
all exceed 5%.
It is worth mentioning that in recent years, no new products of cardiovascular and cerebrovascular proprietary Chinese medicines have been approved for marketing, only Shenzhen Shasong Industry | Henan Tianfang Pharmaceutical's brain-wounded Lesheng granules are under review as new drugs Class 1.
1, in addition, Shanghai Tufeng Pharmaceutical| Jiangsu Kangyuan Pharmaceutical's phlebitis granules, Yunnan Baiyao Group's Quansanqi tablets and other 8 Class 1.
1 new drugs have been approved for clinical trials
.
all exceed 5%.
It is worth mentioning that in recent years, no new products of cardiovascular and cerebrovascular proprietary Chinese medicines have been approved for marketing, only Shenzhen Shasong Industry | Henan Tianfang Pharmaceutical's brain-wounded Lesheng granules are under review as new drugs Class 1.
1, in addition, Shanghai Tufeng Pharmaceutical| Jiangsu Kangyuan Pharmaceutical's phlebitis granules, Yunnan Baiyao Group's Quansanqi tablets and other 8 Class 1.
1 new drugs have been approved for clinical trials
.
3 billion emergency miracle medicine reached a new high, 13 exclusive products "Dominate the screen"
2022E Top 20 Chinese proprietary Chinese medicine products in China's urban physical pharmacies terminal cardiovascular and cerebrovascular medicine (: 100 million yuan)
Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern
com: China's urban physical pharmacy drug terminal competition pattern
The total market share of the TOP20 products exceeds 70%, and the sales volume exceeds 100 million yuan
.
Among them, Angong Niuhuang Pill flourished with more than 3.
8 billion yuan, and Niuhuang Qingxin Pill (Bureau) grew the fastest, exceeding 50%.
From the perspective of treatment subcategories, cardiovascular diseases are the most used drugs, with 11; There are 8 drugs for cerebrovascular diseases and 1 drug for lipid-lowering diseases
.
.
Among them, Angong Niuhuang Pill flourished with more than 3.
8 billion yuan, and Niuhuang Qingxin Pill (Bureau) grew the fastest, exceeding 50%.
From the perspective of treatment subcategories, cardiovascular diseases are the most used drugs, with 11; There are 8 drugs for cerebrovascular diseases and 1 drug for lipid-lowering diseases
.
There are as many as 13 exclusive varieties in the TOP20 products, involving many enterprises
such as Beijing Tongrentang, Tasly, Buchang Pharmaceutical, Yiling Pharmaceutical, Zhongxin Pharmaceutical No.
6 Traditional Chinese Medicine, Shanghai Hehuang Pharmaceutical and so on.
such as Beijing Tongrentang, Tasly, Buchang Pharmaceutical, Yiling Pharmaceutical, Zhongxin Pharmaceutical No.
6 Traditional Chinese Medicine, Shanghai Hehuang Pharmaceutical and so on.
Sales of Angong Niuhuang Pills in Drug Terminal in China's Urban Physical Pharmacies in Recent Years (: 100 million yuan)
Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern
com: China's urban physical pharmacy drug terminal competition pattern
Angong Niuhuang Pill has the effects
of clearing heat and detoxification, calming panic and opening the trick.
It can be used for fever, evil into the pericardium, febrile convulsions, dizziness; Stroke coma and encephalitis, meningitis, toxic encephalopathy, cerebral hemorrhage, sepsis see the above symptoms
.
According to data from Minai.
com, Angong Niuhuang Pill has been firmly ranked as the "first brother" of cardiovascular and cerebrovascular proprietary Chinese medicine in China's urban physical pharmacy terminals for many consecutive years, and its sales exceeded the 3 billion yuan mark for the first time in 2021, and it is expected to reach a new high in 2022, with a year-on-year increase of more than 5%.
Up to now, 120 enterprises in Angong Niuhuang Pill have production
approvals.
of clearing heat and detoxification, calming panic and opening the trick.
It can be used for fever, evil into the pericardium, febrile convulsions, dizziness; Stroke coma and encephalitis, meningitis, toxic encephalopathy, cerebral hemorrhage, sepsis see the above symptoms
.
According to data from Minai.
com, Angong Niuhuang Pill has been firmly ranked as the "first brother" of cardiovascular and cerebrovascular proprietary Chinese medicine in China's urban physical pharmacy terminals for many consecutive years, and its sales exceeded the 3 billion yuan mark for the first time in 2021, and it is expected to reach a new high in 2022, with a year-on-year increase of more than 5%.
Up to now, 120 enterprises in Angong Niuhuang Pill have production
approvals.
In October this year, Kunming Pharmaceutical Group issued an announcement that its wholly-owned subsidiary, Kunming Traditional Chinese Medicine Factory, obtained the "Drug Supplement Application Approval Notice" approved and issued by the State Food and Drug Administration, approving the change of the marketing authorization holder of this product from Heilongjiang Sunflower Pharmaceutical to Kunming Traditional Chinese Medicine Factory
.
KunYao Group said that the approval will further enrich the pipeline of Kunming Traditional Chinese Medicine fine Chinese medicine products, which is conducive to enhancing the company's market competitiveness and brand strength
in the field of fine Chinese medicine.
At the same time, cardiovascular and cerebrovascular diseases are the core therapeutic areas that the company focuses on, and at present, the company has Kunming medicine blood plug series, lamp silver brain capsules and other products, the approval of Angong Niuhuang Pill will further enhance the company's industry position
in the field of cardiovascular and cerebrovascular diseases.
.
KunYao Group said that the approval will further enrich the pipeline of Kunming Traditional Chinese Medicine fine Chinese medicine products, which is conducive to enhancing the company's market competitiveness and brand strength
in the field of fine Chinese medicine.
At the same time, cardiovascular and cerebrovascular diseases are the core therapeutic areas that the company focuses on, and at present, the company has Kunming medicine blood plug series, lamp silver brain capsules and other products, the approval of Angong Niuhuang Pill will further enhance the company's industry position
in the field of cardiovascular and cerebrovascular diseases.
Brand TOP20 sales exceeded 100 million! 5 rose by more than 30%, Tongrentang, Tasly.
.
.
Lead
.
.
Lead
2022E Top 20 Chinese Cardiovascular and Cerebrovascular Chinese Patent Medicine Brands in China's Urban Physical Pharmacy Terminal (: 100 million yuan)
Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern
com: China's urban physical pharmacy drug terminal competition pattern
The sales of the top 20 brands have exceeded 100 million yuan, from the perspective of growth rate, 16 brands have positive year-on-year growth, Jiuzhitang's Angong Niuhuang Pill, Shanxi Guangyu Yuanguo Medicine's Niuhuang Qingxin Pill (Bureau), Beijing Yiling Pharmaceutical's Jiansong Yangxin Capsule, Shandong Hongjitang Pharmaceutical Group's Angong Niuhuang Pill, and Germany's Dr.
Weima Shupei's Ginkgo biloba Extract Tablets have a growth rate of more than 30%.
Among them, Jiuzhitang's Angong Niuhuang Pill and Shanxi Guangyu Yuanguo Medicine's Niuhuang Qingxin Pill (Bureau) entered the TOP20
for the first time.
Weima Shupei's Ginkgo biloba Extract Tablets have a growth rate of more than 30%.
Among them, Jiuzhitang's Angong Niuhuang Pill and Shanxi Guangyu Yuanguo Medicine's Niuhuang Qingxin Pill (Bureau) entered the TOP20
for the first time.
From the perspective of the number of brands, Beijing Tongrentang has 3 on the list, and Buchang Pharmaceutical, Yiling Pharmaceutical, and Guangyuyuan each have 2 on the list
.
.
In recent years, the sales of Niuhuang Qingxin Pill (bureau) in China's urban physical pharmacy drug terminal (bureau) (: 100 million yuan) picture
Source: Minai.
com: China's urban physical pharmacy drug terminal competition pattern
com: China's urban physical pharmacy drug terminal competition pattern
According to data from Minai.
com, the sales of Niuhuang Qingxin Pill (Bureau) in China's urban physical pharmacy terminal have grown rapidly in recent years, and are expected to exceed 200 million yuan in 2022, a year-on-year increase of more than 50%.
At present, there are 35 enterprises with production approvals in Niuhuang Qingxin Pill (Bureau), of which Shanxi Guangyu Yuanguo Pharmaceutical has the largest market share, accounting for more than 70%, and its sales will reach a new high
this year.
com, the sales of Niuhuang Qingxin Pill (Bureau) in China's urban physical pharmacy terminal have grown rapidly in recent years, and are expected to exceed 200 million yuan in 2022, a year-on-year increase of more than 50%.
At present, there are 35 enterprises with production approvals in Niuhuang Qingxin Pill (Bureau), of which Shanxi Guangyu Yuanguo Pharmaceutical has the largest market share, accounting for more than 70%, and its sales will reach a new high
this year.
Source: Minainet database, company announcements
Note: Minai.
com's "Competition Pattern of Drug Terminal in China's Urban Physical Pharmacies", the statistical scope is: physical pharmacies in cities at the prefecture level and above nationwide, excluding county and rural pharmacies; The above sales are calculated
based on the average retail price of the product at the terminal.
If there is any omission, please correct
it.
com's "Competition Pattern of Drug Terminal in China's Urban Physical Pharmacies", the statistical scope is: physical pharmacies in cities at the prefecture level and above nationwide, excluding county and rural pharmacies; The above sales are calculated
based on the average retail price of the product at the terminal.
If there is any omission, please correct
it.
